REG - Uniphar PLC - AGM Results

UnipharAnnouncement

Yesterday 15:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260507:nRSG4755Da&default-theme=true

RNS Number : 4755D  Uniphar PLC  07 May 2026

AGM Results

 

Dublin, London | 7 May 2026

 

Uniphar plc (the Company) announces that at its Annual General Meeting ("AGM")
held at 11.00 a.m. today, 7 May 2026, each of the resolutions set out in the
Notice of Annual General Meeting circulated to shareholders and made available
on the Company's website, www.uniphar.ie (http://www.uniphar.ie/) ,
(http://www.uniphar.ie/) were duly passed without amendment, with the
exception of Resolution 7 which was not passed.

Details of votes cast are set out below:

 

 

       RESOLUTION                                                   For          For %    Against     Against  Withheld

                                                                                                      %
 1     Financial Statements and Reports                             155,801,328  100.00%  -           0.00%    65,198
 2     Final Dividend of                                            155,862,330  100.00%  4,196       0.00%    -

       €3.4m
 3(a)  Re-elect Ger Rabbette                                        155,170,281  99.57%   662,597     0.43%    33,648
 3(b)  Re-elect Tim Dolphin                                         155,132,752  99.55%   700,126     0.45%    33,648
 3(c)  Re-elect Paul Hogan                                          154,475,082  99.11%   1,391,444   0.89%    -
 3(d)  Re-elect Sue Webb                                            153,396,166  98.44%   2,436,712   1.56%    33,648
 3(e)  Re-elect Jim Gaul                                            143,860,681  92.32%   11,972,197  7.68%    33,648
 3(f)  Re-elect Liz Hoctor                                          155,516,769  99.78%   349,757     0.22%    -
 3(g)  Re-elect Maurice Pratt                                       149,269,506  95.78%   6,569,125   4.22%    -
 3(h)  Re-elect Valerie Sick                                        154,441,434  99.11%   1,391,444   0.89%    33,648
 4     Remuneration of Auditors                                     132,756,119  85.17%   23,109,607  14.83%   800
 5     Authority to allot relevant securities                       125,718,359  80.66%   30,148,167  19.34%   -
 6     Disapplication of pre- emption rights in                     155,282,158  99.63%   583,568     0.37%    800

       specified circumstances
 7     Disapplication of pre- emption rights in additional          103,983,762  66.71%   51,882,764  33.29%   -

       Circumstances*
 8     Authorise market purchases of the Company's Ordinary Shares  155,455,359  100.00%  -           0.00%    411,167
 9     Re-issuance of Treasury Shares                               155,866,526  100.00%  -           0.00%    -

 

*The Board notes that Resolution 7, relating to the dis-application of
pre-emption rights in certain additional circumstances, was not passed at the
AGM. Resolution 7 was proposed on terms consistent with the Statement of
Principles on Disapplying Pre-emption Rights published by the Pre-emption
Group in November 2022 (the "Statement of Principles") and the Directors
believe that this resolution is appropriate in order to maintain flexibility
to allot additional securities within the circumstances contemplated by the
terms of the resolution and the Statement of Principles. In accordance with
provision 4 of the UK Corporate Governance Code (the "Code"), the Board
confirms that it will engage with shareholders to understand and discuss the
reasons behind the votes received against this resolution. An update on the
views received from shareholders and actions taken will be provided within six
months of the Annual General Meeting, in accordance with the Code.

 

--- ENDS ---

 

Contact details
 Uniphar Group                                            Tel: +353 (0) 1 428 7777

 Allan Smylie, Head of Strategy and IR

 Davy (Joint Corporate Broker, Nominated Advisor and      Tel: +353 (0) 1 679 6363

 Euronext Growth Listing Sponsor)

 Daragh O'Reilly

 Niall Gilchrist

 Ivan Murphy

 RBC Capital Markets (Joint Corporate Broker)             Tel: +44 (0) 20 7653 4000

 Jamil Miah

 Daniel Saveski

 Stifel Nicolaus Europe Limited (Joint Corporate Broker)  Tel: +44 (0) 20 7710 7600

 Matt Blawat

 Ben Maddison

 Francis North

 Q4 PR                                                    Tel: +353 (0) 1 475 1444

 Iarla Mongey, Public Relations Advisor to Uniphar Group

 

About Uniphar plc

Headquartered in Dublin, Ireland, the Uniphar Group is an international
diversified healthcare services business servicing the requirements of more
than 200 multinational pharmaceutical and medical technology manufacturers
across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply
Chain & Retail. The Group is active in Europe, North America, APAC and
MENA and delivers to 160+ countries.

The Company's vision is to improve patient access to pharmaco-medical products
and treatments by enhancing connectivity between manufacturers and healthcare
stakeholders. Uniphar represents a strong combination of scale, growth, and
profitability.

Uniphar Supply Chain & Retail

Uniphar Supply Chain & Retail is the leading pharmaceutical wholesaler in
Ireland with a growing symbol group offering of retail pharmacies. The Group's
strategy for Uniphar Supply Chain & Retail is to grow our wholesale market
share, our symbol group network and our own brand, in-licenced and consumer
products portfolio.

Uniphar Medtech

Uniphar Medtech is a leading Pan-European medical device distributor and
solutions partner. The Group's strategy for Uniphar Medtech is to grow our
service offering across Europe and expand our addressable market by serving
new specialities and new manufacturers.

Uniphar Pharma

Uniphar Pharma operates a global business with high value services across the
lifecycle of a pharmaceutical product. We enable pharma and biotech companies
to bring innovative medicines to global markets and provide healthcare
professionals with access to medicines they can't source through traditional
channels. Our strategy is to build a leading platform to provide the
specialist support and expertise needed to improve access to these medicines.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGAKOBDNBKDFPK



            Copyright 2019 Regulatory News Service, all rights reserved